



Ventripoint Expands to Address the Needs of Companion Animals

Toronto, Ontario – The Newswire – January 11, 2021 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) announces that it has entered into a Collaboration Agreement with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.

Dr. Bruce W Keene, DVM, MSc, DACVIM of NC State Veterinary Medicine commented, "NC State Cardiology is pleased to be a part of the development and preliminary testing of a potential veterinary application of the Ventripoint echocardiography system. More accurate and complete echocardiographic estimates of cardiac dimensions and volumes would provide a major advance for veterinary echocardiography. The potential to use Ventripoint's artificial intelligence-based software to allow us to reliably visualize the heart in 3-dimensions from routinely acquired 2-dimensional data would contribute significantly to the case management of both congenital and acquired heart diseases in animals."

A Bank of America survey found 37% of Americans have adopted a pet since the start of the COVID pandemic. All these animals will need some form of veterinary care as they grow older. According to the American Veterinary Medical Association (AVMA), the pet dog population in the United States is estimated to be 77 million dogs (AVMA Pet Ownership and Demographics Sourcebook, 2017-2018 Edition) with approximately 10% of all dogs having heart disease (estimated to be 7.8 million dogs; Dogs and Heart Disease: An Overview; www.pethealthnetwork.com). The true prevalence of cardiovascular disease is likely underestimated because most domestic animals do not receive a cardiac workup.

This is a natural progression for Ventripoint and evolution of our technology. With this study, Ventripoint can diversify its product portfolio and expand our innovative technology to advance cardiac care for animals. The aim is to provide a solution for veterinarians that will ultimately be applicable to all animals.

"Companion animals have heart problems, like their owners and so we are delighted to broaden our products to include veterinary services," stated Dr. George Adams, Executive-Chairman of Ventripoint. "Initial studies at NCSU have shown the VMS+3.0 can accurately reconstruct and measure the function of canine hearts and this more in-depth evaluation in collaboration with NCSU will verify the results."

There are approximately 30,000 veterinary practices in the United States according to the American Veterinary Medical Association. Thousands of these clinics offer echocardiography services without having a board-certified veterinary cardiologist on

staff. The ease of use of the VMS+3.0 will allow a better initial assessment of dogs and if necessary, the easy transfer of the studies to a board-certified veterinary cardiologist for further review.

The ease of use of the VMS+3.0 will allow a better initial assessment of dogs and if necessary, the easy transfer of the studies to a board-certified veterinary cardiologist for further review.

Equipping and training veterinarians on cardiac assessment using 2D ultrasound and the VMS+3.0 analysis system would enable many more companion animals to be properly evaluated and treated. Like all cardiac disease, early detection and treatment is critical to achieving a long-term outcome.

Ventripoint is expanding to improve the care of all humans and their best friends.

About the North Carolina State University Veterinary Hospital and College of Veterinary Medicine

The Veterinary Hospital is an integrated health care center for companion, equine and farm animals. We exist to further the teaching mission of the College of Veterinary Medicine and to provide state-of-the-art patient care. About 23,000 cases, primarily companion animals and horses, are diagnosed and treated annually by the Veterinary Hospital. The College involves some 155 faculty, 400 staff members, and it enrolls more than 300 Doctor of Veterinary Medicine (DVM) students, 80 graduate students, and 75 interns and residents. A component of these research activities, the Center for Comparative Medicine and Translational Research (CCMTR) is a community of more than 100 scientists who are involved in collaborative studies with government, private, and other academic researchers to advance the knowledge and practical applications that improve animal and human health. According to the 2019, U.S. News & World Report, the North Carolina State University College of Veterinary Medicine was ranked 4th in the USA (<https://www.usnews.com/best-graduate-schools/top-health-schools/veterinarian-rankings>).

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams
gadams@ventripoint.com
Tel: 519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.